Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13161883 | 0.96 | ALDH1A1 (0.50) | SMN1; SMN2MAPK1SIRT6ALDH1A1MAPT | |
| SCHEMBL7298034 | 0.91 | ALDH1A1 (0.51) | SMN1; SMN2MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL13634150 | 0.89 | SIRT6 (0.55) | SMN1; SMN2MAPK1SIRT6ALDH1A1MAPT | |
| SCHEMBL147701 | 0.89 | MAPT (0.53) | SMN1; SMN2MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL2771188 | 0.89 | SIRT6 (0.53) | SMN1; SMN2SIRT6ALDH1A1MAPTLMNA | |
| SCHEMBL495726 | 0.88 | SIRT6 (0.54) | MAPK1SIRT6ALDH1A1MAPTLMNA | |
| SCHEMBL378383 | 0.87 | SIRT6 (0.65) | SMN1; SMN2MAPK1SIRT6ALDH1A1MAPT | |
| SCHEMBL13161884 | 0.86 | KDM4E (0.52) | SMN1; SMN2MAPK1SIRT6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL378382 | 0.86 | SIRT6 (0.64) | SMN1; SMN2MAPK1SIRT6ALDH1A1MAPT | |
| SCHEMBL13634261 | 0.85 | SIRT6 (0.51) | MAPK1SIRT6ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| CN-101835764-B | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC | 2012-09-19 | — | — | CN | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| CN-101835764-A | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC | 2010-09-15 | — | — | CN | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | SMN1; SMN2 3213/4885MAPK1 307/4885SIRT6 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.